1. Home
  2. SONO vs PVLA Comparison

SONO vs PVLA Comparison

Compare SONO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonos Inc.

SONO

Sonos Inc.

HOLD

Current Price

$15.81

Market Cap

1.9B

ML Signal

HOLD

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

HOLD

Current Price

$139.89

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONO
PVLA
Founded
2002
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
SONO
PVLA
Price
$15.81
$139.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
15
Target Price
$19.67
$171.87
AVG Volume (30 Days)
1.8M
143.3K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
52.62
EPS
0.77
N/A
Revenue
$1,443,276,000.00
$42,810,000.00
Revenue This Year
$5.04
N/A
Revenue Next Year
$6.53
$104,350.18
P/E Ratio
$20.84
N/A
Revenue Growth
N/A
65.28
52 Week Low
$12.44
$49.13
52 Week High
$19.82
$161.38

Technical Indicators

Market Signals
Indicator
SONO
PVLA
Relative Strength Index (RSI) 51.78 43.21
Support Level $15.77 $135.30
Resistance Level $17.26 $147.47
Average True Range (ATR) 0.67 8.03
MACD -0.02 -1.91
Stochastic Oscillator 42.65 18.24

Price Performance

Historical Comparison
SONO
PVLA

About SONO Sonos Inc.

Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Share on Social Networks: